The thesis
PanicFade v4 is built on a simple, well-documented market reflex: negative headline shocks tend to be overreacted to, and prices drift back toward fundamentals. The strategy only acts when two conditions coincide — a sentiment reading below -0.4 and a name that is already technically oversold (RSI14 under 35, trading below its SMA20). It then sizes into the panic rather than away from it. Exits are symmetric and rule-bound: it takes profit on reversion (RSI14 above 50 or a reclaimed SMA20) and hard-stops fresh lows on continued negativity, treating that as a genuine fundamental break rather than noise.
The approach is grounded in recent sentiment-feedback literature (arXiv:2509.11970, 2025, plus corroborating work in JRFM/MDPI). The universe is deliberately conservative — 24 mega- and large-cap names across tech, financials, healthcare, staples and energy — which keeps liquidity high and limits the tail risk of fading a genuinely broken small cap.
Recent activity
Trading has been quiet, and that is by design. Four of the last six scheduled runs executed nothing at all; the strict dual gate (sentiment and oversold) simply wasn't met. The 1 October run was the exception, firing two orders: a 5-share MCD buy at $231.79 and a 21-share BAC exit at $53.60.
That BAC round-trip is instructive. The position was opened on 15 September at $59.86 and closed at $53.60 — a loss of roughly $6 per share. This looks like the hard-stop doing its job: a fade that kept falling, cut rather than averaged into oblivion. Contrast it with WMT, bought at $103.12 on 28 August and sold at $107.48 on 21 September for a clean reversion-driven gain. The engine is cutting losers and banking mean-reversion winners as intended.
The live paper account, however, has drifted sideways-to-down, with total equity slipping from $9,864 (29 Sep) to $9,778 (6 Oct) against idle cash of $5,721. Roughly half the book sits uninvested — a direct consequence of the selective entry logic.
Validation and performance
This is where PanicFade v4 earns attention. Across four walk-forward folds from 2021 to 2026, all four were positive, and performance improved over time — from a marginal 1.6% (Sharpe 0.19) in the 2022 drawdown era to 21.7% (Sharpe 2.44) in the most recent out-of-sample window. A probabilistic Sharpe ratio of 0.985 and a deflated Sharpe of 0.56 across 27 trials suggest the edge is unlikely to be pure overfitting.
The honest caveats
The headline 37.93% return flatters a 1,233-day backtest: the CAGR is a modest 6.79%, and the aggregate Sharpe of 0.96 is respectable but not spectacular. Turnover near 5,800% means the strategy is fee-sensitive, and the recent live flatness is a reminder that a patient fader spends long stretches doing nothing. The strong recent OOS fold may also reflect a favourable regime rather than a permanent step-change. Clean validation, real risk controls — but temper expectations to the 6–7% annualised range the full history actually supports.